HealthQuill EU
Novo Nordisk’s medicine Wegovy, at a higher dose, resulted in an average weight loss of 21% during trials in people with obesity compared to a dummy drug, the company stated.
Drugs Health Pharma

Wegovy’s weight-loss efficacy improves with higher dosage

HQ Team June 21, 2025: Novo Nordisk’s medicine Wegovy, at a higher dose, resulted in an average weight loss of 21% during trials.

Read More
Franco-Italian EssilorLuxottica SA got approval from the Food and Drug Administration to market its over-the-counter audio glasses in the US for people with hearing loss.
Health Medical Pharma

EssilorLuxottica gets regulator nod for audio glasses in US, EU for hearing loss

Franco-Italian EssilorLuxottica SA got approval from the Food and Drug Administration to market its over-the-counter audio glasses in the US for people with.

Read More
The European Union regulators have greenlighted AstraZeneca’s drug to treat an advanced form of non-small cell lung cancer after it reduced the death rate by 84%.
Drugs Medical Pharma

EU greenlights AstraZeneca’s non-small cell lung cancer drug

The European Union regulators have greenlighted AstraZeneca’s drug to treat an advanced form of non-small cell lung cancer after it reduced the death.

Read More
Negotiators at a global climate conference signed a $300 billion-a-year deal to finance emissions reduction — that developing nations say falls way short of their expectations.
Climate Health Pharma

Global warming on backburner; vexed financing deal sees light at COP29 

Global representatives at a climate conference signed a $300 billion-a-year deal to finance emissions reductions — a move developing nations say falls way.

Read More
Johnson & Johnson has submitted regulatory applications to the US drug regulator and European Medicines Agency (EMA) for the extended approval of a blood cancer therapy.
Drugs Health Pharma

J&J seeks approval for its blood cancer therapy in US, European Union

Johnson & Johnson has submitted regulatory applications to the US drug regulator and European Medicines Agency (EMA) for the extended approval of a blood.

Read More
Danish multinational pharmaceutical company Novo Nordisk’s end-stage trial in patients with fatty liver disease saw reduced liver scarring (fibrosis) and its resolution without worsening the condition.
Drugs Health Pharma

Novo Nordisk’s weight loss drug reduces liver scarring in end-stage trial

Danish multinational pharmaceutical company Novo Nordisk’s end-stage trial in patients with fatty liver disease saw reduced liver scarring (fibrosis) and its resolution without.

Read More
Israel has passed a law to ban the United Nations Relief and Works Agency from operating in the country after it earlier accused its employees of participation in the October 7 attacks — a move which came in for criticism from Western European leaders.
Drugs Health Medical

Israel bans UN relief agency, EU, Western European leaders slam move 

Israel has passed a law to ban the UN relief agency, UNRWA, from operating in the country after it earlier accused its employees.

Read More
AstraZeneca Plc’s drug Fasenra got approval from the European Union regulator for treating adult patients with a rare inflammation of blood vessels.
Drugs Health Pharma

AstraZeneca’s drug to treat rare blood vessel disease gets EU nod

AstraZeneca Plc’s drug Fasenra got approval from the European Union regulator for treating adult patients with a rare inflammation of blood vessels.

Read More
Danish pharmaceutical company, Novo Nordisk’s oral semaglutide drug to treat type 2 diabetes helped reduce heart diseases by 14% compared to a dummy medicine in a trial, according to a statement.
Drugs Health Pharma

Novo’s type 2 oral diabetic drug cuts heart diseases by 14% in a trial

Danish pharmaceutical company, Novo Nordisk’s oral semaglutide drug to treat type 2 diabetes helped reduce heart diseases by 14% compared to a dummy.

Read More
The US Food and Drug Administration approved AstraZeneca Plc’s Fasenra for treatment in adult patients with a rare inflammation of blood vessels.
Drugs Health Pharma

AstraZeneca’s rare disease drug Fasenra gets US regulator’s nod

The US Food and Drug Administration approved AstraZeneca Plc’s Fasenra for treatment in adult patients with a rare inflammation of blood vessels.

Read More